graft-versus-host disease

[Bone Marrow Transplantation] Further preclinical and clinical studies will explore defibrotide’s potential utility in a broader range of disorders resulting from endothelial cell activation and dysfunction.

[Blood Advances] Investigators reported results of a prospective pilot trial evaluating the safety/feasibility of peri-transplant administration of ruxolitinib for myelofibrosis treatment. Peri-HCT ruxolitinib was safe and well-tolerated with the maximum tolerated dose determined as 10 mg BID, associated with dose-dependent PK and cytokine profile.

[Bone Marrow Transplantation] The difference in the effect of killer immunoglobulin-like receptor–ligand mismatch was retrospectively assessed between patients who received cord blood transplantation for acute leukemia, myelodysplastic syndrome, or chronic myeloid leukemia, as well as GVHD prophylaxis comprising tacrolimus plus methotrexate or mycophenolate mofetil.

[Nature Biomedical Engineering] The authors showed that the pharmacokinetics and half-life of IL-2 could be substantially improved by orthogonally conjugating the cytokine to poly(ethylene glycol) (PEG) moieties via a copper-free click reaction through the incorporation of azide-bearing amino acids at defined sites.

[Blood Advances] Scientists compared overall survival between haploidentical hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamid and HLA-matched sibling donor, 8/8 HLA-matched unrelated donor, 7/8 HLA-matched UD, or umbilical cord blood HCT.

[Bone Marrow Transplantation] Investigators aimed to modify the immune response in the long term after allogeneic bone marrow transplantation by using the proteasome inhibitor ixazomib at the late stages of the post-transplant period.